MRVI logo

MARAVAI LIFESCIENCES HLDGS-A

MRVINASDAQ
πŸ† #1807 by market capEarnings Nov 4 Β· PostUS Equity
$606.29β–² $6.91 (+1.14%)
Simulated price
1hβ€”
24hβ–² 1.1%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$1.50B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-3.3%
Declining
πŸ“ŠGross Margin
34.9%
Moderate
πŸ’΅FCF Margin
3.8%
Moderate
βš–οΈP/S Ratio
7.5x
Fair
Otter Score
55
Weak
No chart data available for MRVI.

Trading Snapshot

Day Range
$600.59 – $615.11
52-Week Range
$2.03 – $7.44
Volume
$2.51B
Avg Volume
$2.37B
Shares Outstanding
258.2M
Next Earnings
Sep 6, 2026

Fundamentals Snapshot

Annual Revenue
$186M
Last Q Revenue
$51M
P/E Ratio
β€”
P/S Ratio
7.5x
EPS (TTM)
$-0.53
Dividend Yield
β€”

Why Investors Own MRVI

  • βœ“High-growth profile β€” revenue up +56.0% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 58% gross margin and 25% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$186Mβ–² +55.0% YoY
Gross Margin (TTM)
57.5%β–² +2.2% YoY
Operating Income (TTM)
$20Mβ–² +55.0% YoY
Free Cash Flow (TTM)
$47Mβ–² +55.0% YoY

About MARAVAI LIFESCIENCES HLDGS-A

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
55/100

Analyst Price Target

β“˜
Average Target
$714.12
β–² +17.8% Upside
High Target$812.92
Low Target$552.38
Based on 15 analysts

Latest News & Updates